AstraZeneca has reported promising results from trials for lung cancer drugs.
Showing promise was a late-stage trial of its cancer drug Tragrisso.
The Phase III Flaura trial was used which was used in the treatment of forms of non-small cell lung cancer.
Results of the Phase III Flaura trial were included at the Presidential Symposium I of the European Society of Medical Oncology 2017 Congress in Madrid, Spain.
Sean Bohen, executive vice president, Global Medicines Development and Chief Medical Officer at AstraZeneca, said: “The Flaura data suggest early and sustained benefit with Tagrisso that has the potential to significantly impact long-term patient outcomes and help address the considerable unmet need that remains.”
AstraZeneca and MedImmune, its global biologics research and development arm, also presented data from a planned interim analysis of the Phase III Pacific trial for a type of non-small cell lung cancer.
Results of the Pacific trial were also included at the Presidential Symposium I.
Bohen, stated: “The Phase III Pacific results are incredibly encouraging for a patient population that until now has been without treatment options.”
The Endpoints website and newsletter reported the two trials were good news for a company that has seen its share of setbacks in working to bolster its drug pipeline.